RBSH stock surged to $0.0001, a 9,900.00% one-day gain on the PNK exchange during U.S. market hours on 04 Mar 2026. The spike came on light volume of 2,141 shares and pushed market capitalization to roughly USD 3,213. We review the drivers, fundamental metrics and the short-term technical picture to help traders understand where momentum may lead next.

RBSH stock price action and volume

RBSH stock closed at $0.0001 on PNK after opening at the same level today. Trading volume reached 2,141 shares versus an average daily volume of 3,023, indicating above-average interest for a microcap. The previous close was $0.000001, which explains the reported 9,900.00% change for the session.

RBSH stock catalysts and news context

Rebus Holdings, Inc. (RBSH) lists RT-AR001 as its lead oncology asset and remains active in early-stage development. There is no company press release tied to the price jump today, so momentum likely reflects thin-market trading or a small block trade. Traders should check official filings and the company site for updates at Rebus Holdings.

RBSH stock fundamentals and valuation

RBSH shows a market cap near USD 3,213, shares outstanding 32,130,000, EPS 0.02, and a reported PE of 0.01 in the raw data. Trailing metrics show negative book value per share of -0.1645871963292372 and operating cash flow per share of -0.0221880008799773, reflecting an early-stage biotech with limited revenue and cash runway concerns.

RBSH stock technicals and Meyka AI grade

Technical indicators show an RSI of 51.85 and CCI at 116.67, signaling short-term strength on a low liquidity name. Meyka AI rates RBSH with a score out of 100: 64.59 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus and forecasts. These grades are informational and not investment advice.

RBSH stock risks and sector context

RBSH operates in the Healthcare sector and Biotechnology industry in the United States, where small-cap drug developers face binary clinical and financing risk. The company lists 10 employees and limited cash per share (0.0001571388164304). Debt-to-assets sits at 62.00 and current ratio is near 0.00095, highlighting liquidity risk for holders.

RBSH stock outlook and price targets

Meyka AI’s forecast model projects a one-year estimate of 0.0027497791398693513 USD per share from a current price of 0.0001 USD. That implies an upside of about 2,649.78% versus today. Reasonable scenario price targets: conservative $0.0001, base $0.0027, optimistic $0.0100. Forecasts are model-based projections and not guarantees.

Final Thoughts

RBSH stock’s 04 Mar 2026 spike to $0.0001 produced a headline move on PNK but came with low absolute liquidity and no clear public announcement. We see a classic microcap setup: high percentage moves on tiny share volumes and exposed downside if support fails. Meyka AI’s grading flags a B | HOLD stance, reflecting the company’s early-stage biotech profile, limited cash per share, and small market cap of USD 3,213. Our forecast model projects USD 0.0027497791398693513 in 12 months, an implied upside of roughly 2,649.78%, but we stress forecasts are projections and not guarantees. Traders should verify company filings, monitor OTC/PNK liquidity, and treat positions in RBSH stock as speculative within a diversified portfolio. For live updates and technical alerts, see our RBSH page at Meyka RBSH page and the company site at Rebus Holdings.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.